1 of 1
Story summary
- A gene therapy for lung cancer has shown promise by shrinking tumors with immune-boosting genes delivered to lung cells.
- Krystal Biotech developed the therapy using a modified herpes virus, fast-tracked by the U.S. Food and Drug Administration (FDA).
- In trials, tumor size reduced in three of eleven patients; five others halted growth.
- The approach is limited to lung tumors; ongoing trials will involve about 250 patients testing combinations.
